Bioworld Technology CO., Ltd.

SLU7 Peptide

Cat No.: BS5936P

Background

In order to produce correctly spliced messenger RNA, two catalytic splicing steps are required. After catalytic step I, a major remodeling of the spliceosome occurs to establish the active site for step II. During the second step of mRNA splicing, exon 1 attacks an adenine-guanine (AG) dinucleotide at the 3' splice site. SLU7, the human homolog of the yeast step II splice factor Slu7, is required for selection of the correct AG. Human SLU7 associates with the spliceosome late in the splicing pathway prior to recognition of the 3' splice site for step II. SLU7 depletion in HeLa nuclear extract reveals that SLU7 is required to hold exon 1 tightly within the spliceosome for attack on a prespecified AG.

Swiss-Prot

O95391

Applications

Blocking

Specificity

This peptide can be used with studies using BS5936 SLU7 pAb.

Purification & Purity

Synthetic peptide SLU7. (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4℃ short term. Aliquot and store at -20℃ long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.

Bioworld Technology, Inc.
1660 South Highway 100, Suite 500 St. Louis Park,MN 55416,USA. **Email: info@bioworlde.com**
Tel: 6123263284 **Fax: 6122933841**

Bioworld technology, co, Ltd.
No 9, weidi road Qixia District Nanjing, 210046, P, R.China. **Email: info@biogot.com**
Tel: +86-025-68037686 **Fax:+86-025-68035151**